PUBLISHER: iData Research Inc. | PRODUCT CODE: 1847186
PUBLISHER: iData Research Inc. | PRODUCT CODE: 1847186
Please contact us using the inquiry form for pricing information.
The U.S. standard peripheral vascular device market was valued at over $2.7 billion in 2024. The market is expected to reach over $3.5 billion by 2031.
This report suite covers inferior vena cava filters and retrieval devices, carotid shunts, transcarotid arterial revascularization flow reversal systems and stents, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths, vascular closure devices, and transcatheter embolization devices.
While some of these technologies can be used in coronary care, all sizing and forecasts in this study reflect peripheral procedures only.
The research quantifies unit sales, average selling prices, market size, growth rates, procedure numbers, and company shares.
It also analyzes market drivers and limiters, mergers and acquisitions, portfolios, and the competitive landscape across hospitals, ambulatory sites, and office based labs.
Market Overview
Peripheral vascular programs in the United States continue to shift toward minimally invasive care across arterial and venous pathways.
Hospitals and office based labs rely on guidewires, catheters, sheaths, and embolization tools for a wide range of indications.
Carotid protection and treatment are supported by carotid shunts and TCAR systems that allow flow reversal and stenting with neuroprotection. Inferior vena cava filters and retrieval devices address selected patients at risk for pulmonary embolism.
Vascular closure devices are used after percutaneous access and are central to same day discharge and rapid ambulation goals.
Across product lines, the market reflects several broad themes.
First, there is steady movement from invasive or suture-based closure toward non-invasive and extravascular options, in line with radial access protocols and outpatient recovery targets.
Second, demand in office based labs keeps growing, which raises the importance of price corridors, bundles, and consistent supply. Third, device preference is linked to workflow.
Hydrophilic guidewires and supportive catheters shorten case time and improve crossing success. Plug-based and adhesive-based closure systems are valued for ease of use and favorable safety profiles.
Finally, the overall market is influenced by disease awareness, aging demographics, and the continued development of venous treatments that were historically underdiagnosed or undertreated.
Market Drivers
Venous market development. Venous disease remains common and is a major clinical burden. The United States records about 600,000 pulmonary embolism cases per year. Most originate from deep vein thrombosis in the legs. About 79 percent of patients who present with pulmonary embolism show evidence of deep vein thrombosis, and pulmonary embolism occurs in up to half of patients with proximal deep vein thrombosis. Diagnosis can be difficult. Sudden death is the first symptom in a meaningful share of cases, and up to half of patients have no symptoms. About 900,000 people in the United States are affected by deep vein thrombosis each year. As education, screening, and treatment pathways expand, the venous segment of the peripheral market is expected to grow.
Imaging-guided venous interventions. Adoption of intravascular ultrasound is closely linked to deep venous work. Following positive clinical experience and targeted education, penetration of intravascular ultrasound in deep venous procedures already exceeds 50 percent in some programs. Wider use of intravascular ultrasound supports more accurate lesion assessment and stent sizing, which lifts pull-through for guidewires, catheters, and sheaths within the same case.
High restenosis rates drive follow-up intervention. Roughly one third of patients experience re-narrowing after balloon angioplasty. Repeat procedures support steady demand for balloons, guidewires, support catheters, and embolization devices in specific indications. In stented segments, in-stent restenosis can lead to plaque removal with atherectomy or specialty balloons in adjacent markets, and it also supports demand for diagnostic and interventional consumables within the standard suite.
Site of care evolution. More peripheral cases are performed in ambulatory settings and office based labs. These sites prize devices that shorten procedure time, standardize kits, and enable same day discharge. Non-invasive closure technologies fit this need by reducing complications and recovery time.
Market Limiters
Paclitaxel caution spills over to price sensitivity. Although drug-coated products are detailed more deeply in complex suites, the 2018 safety signal and the 2019 FDA review created long-lasting caution that influences purchasing behavior. Hospitals and office based labs scrutinize value across the basket of peripheral tools, which adds pressure to pricing in standard categories as well.
Competition and bundling in office based labs. Office based labs buy at prices that are already below hospital levels. Vendors compete hard for preferred supplier status and often bundle sheaths, guidewires, and catheters with other devices. Bundles lower average selling prices and can challenge smaller firms with narrower portfolios. If market power concentrates, innovation can slow.
Maturing femoral-popliteal segment. As treatment practices become stable in the femoral-popliteal region, growth moderates toward procedural trends rather than rapid expansion. This affects pull-through for wires, catheters, and closure products used in those pathways.
Market Coverage and Data Scope
Quantitative coverage. Market size, market shares, market forecasts, growth rates, units sold, average selling prices, and procedure numbers.
Qualitative coverage. Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA clearances and recalls where relevant, disruptive technologies, and disease overviews that influence therapy selection.
Time frame. Base year 2024, forecasts 2025 to 2031, historical data 2021 to 2023.
Data sources. Primary interviews with industry leaders, government physician and procedure data, regulatory data, hospital and office based lab inputs, import and export data, and the iData Research internal database.
Method note. Revenues are modeled as units multiplied by ASP and validated against installed base, procedure mix, access approach, and setting shifts.
Markets Covered and Segmentation
Inferior Vena Cava Filter Market
Device type. IVC filter and IVC filter retrieval device.
Carotid Shunt
Transcarotid Artery Revascularization (TCAR)
Device type. Transcarotid bare-metal stent and TCAR neuroprotection or flow reversal system.
Diagnostic and Interventional Catheter Market
Device type. Diagnostic catheter and support catheter.
Diagnostic and Interventional Guidewire Market
Device type. Standard and hydrophilic.
Introducer Sheath Market
Device type. Standard and guiding.
Vascular Closure Device Market
Device type. Non-invasive and invasive.
Approach. Radial and femoral.
Transcatheter Embolization Market
Device type. Particle, coil, liquid, and plug.
Approach. Radial and femoral.
Competitive Analysis
Terumo led the U.S. peripheral vascular device market in 2024 on the strength of guidewires and vascular closure devices. The company also held top positions in diagnostic and interventional catheters and in introducer sheaths. Terumo dominated the hydrophilic guidewire segment with Glidewire products that combine a kink-resistant nitinol core and a radiopaque jacket. Variants with softer tips and enhanced visibility serve complex anatomy. The company has used selective price reductions on guidewires to protect share. Terumo secured leadership in the U.S. closure device market after acquiring Angio-Seal and FemoSeal in 2016
Boston Scientific ranked second after expanding its portfolio with the 2019 acquisition of BTG. The company leads in transcatheter embolization devices and holds positions in venous stents with the VICI system, while the long-standing Wallstent continues to contribute share. Boston Scientific has focused on oncology and deep vein thrombosis care, which supports demand for embolization tools and peripheral access consumables.
Abbott Vascular held the third-largest share in 2024, driven by dominance in large-bore vascular closure. Suture-mediated systems such as StarClose, Perclose, and ProStar XL seal arterial access with needles and knots. Abbott has improved stability and ease of use while reducing inflammation risk. The company held a near monopoly in large-bore invasive closure in 2024. Its position may face pressure as newer single-device closure solutions enter the market, but those alternatives have not yet reached the same traction.
Other participants compete across catheters, wires, sheaths, closure, and embolization with strategies that focus on coating performance, pushability, visualization, and service support for multi-site groups and office based labs.
Technology and Practice Trends
Non-invasive and extravascular closure gains. Programs that target same day discharge favor closure devices that reduce complications and allow faster ambulation. Plug-based and adhesive-based systems are gaining share where they fit workflow and safety goals. Clinical guidance and reimbursement support this shift.
Radial first where appropriate. Radial access supports patient comfort and earlier mobilization. It also aligns with outpatient and office based lab pathways. As radial use grows, demand shifts toward compatible introducers, hydrophilic guidewires, and closure strategies designed for radial arteries.
Hydrophilic coatings and supportive catheter design. Crossing success depends on friction, torque, and distal support. Hydrophilic guidewires reduce resistance. Support catheters stabilize the system and aid device delivery. These features reduce case time and limit complications.
TCAR pathway adoption. Flow reversal and neuroprotection are central to TCAR. Systems designed for this approach are expanding the options for carotid treatment.
Embolization portfolio breadth. Physicians choose among particles, coils, liquids, and plugs based on anatomy and flow. Delivery systems are improving in pushability and control, which supports more targeted therapy.
Care Settings
The report covers hospitals, community sites with peripheral programs, ambulatory centers, and office based labs. Site differences affect product choice, kit standardization, and price. Hospitals value broad inventory and support for complex cases. Office based labs focus on cost, consistent delivery, and simple kits that match high-volume protocols. Ambulatory centers target short stays and predictable recovery, which supports non-invasive closure devices and radial access where indicated.
Where is the largest and fastest growing opportunity within the U.S. standard peripheral vascular device market, and how do closure devices, access tools, diagnostic and interventional consumables, embolization systems, carotid shunts, and TCAR components each contribute to value through 2031.
How does the standard peripheral device market relate to the broader U.S. provider landscape, including the shift to outpatient care, growth of office based labs, and pressure on budgets and staffing.
What forces will shape the market going forward, including the rise of non-invasive and extravascular closure, radial first protocols, and the continued development of venous pathways that rely on accurate imaging and device delivery.
What is the expected balance between radial and femoral access, and how will this choice change demand for introducer sheaths, guiding sheaths, closure devices, hydrophilic guidewires, and hemostasis valves across hospitals and office based labs.
How will embolization usage evolve across trauma, bleeding control, and targeted therapy, and what does this mean for the mix of particles, coils, liquids, and plugs, as well as delivery system preferences.
Where will TCAR see the most consistent growth, and how will neuroprotection system placements drive stent pull-through and service requirements for teams that manage carotid disease.
The U.S. standard peripheral vascular device market report from iData Research answers these questions with segment and setting models, company share analysis, procedure and pricing detail, and coverage that links access and closure choices to device consumption.
Use it to size opportunities by category, plan product roadmaps, align bundles and contracts with site needs, and set targets for inventory, service, and training.
Table Of Contents
List Of Figures
List Of Charts
U.S. Standard Peripheral Vascular Device Market Overview
Competitive Analysis
Emerging Markets And Technologies
Market Trends
Market Developments
Procedure Segmentation
Procedure Codes Investigated
Market Segmentation
Key Analysis Updates
Version History
Research Methodology
Impact Of Global Tariffs
U.S. Standard Peripheral Vascular Device Market Overview
Procedure Numbers
Inferior Vena Cava Filter & Retrieval Device Market
Carotid Shunt Market
Transcarotid Artery Revascularization Market
Diagnostic & Interventional Catheter Market
Diagnostic & Interventional Guidewire Market
Introducer Sheath Market
Vascular Closure Device Market
Transcatheter Embolization Device Market
Please contact us using the inquiry form for pricing information.